Francesco Mantuano

机构：Azienda USL di Bologna, University of Bologna · ORCID：0009-0005-3111-5067

发表论文 27 篇 · 总被引 67 次 · h-index 4

代表论文

• Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis (2025 · The Lancet Oncology · 被引 43)
• First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC (2025 · Clinical Cancer Research · 被引 9)
• Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data (2025 · Cancers · 被引 8)
• Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% (2025 · ESMO Open · 被引 4)
• Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC) (2026 · ESMO Open · 被引 1)
• PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression (2026 · JAMA Oncology · 被引 1)